Introduction
============

Guidelines recommend *Helicobacter pylori* eradication in patients who undergo distal gastrectomy for treatment of gastric neoplasia \[[@b1-crt-2015-264]\]. Despite these recommendations, several studies have reported poor long-term outcomes in patients negative for *H. pylori* infection after gastrectomy \[[@b2-crt-2015-264]-[@b4-crt-2015-264]\]. In these studies, negative *H. pylori* status was an independent poor prognostic factor for overall survival (OS) \[[@b2-crt-2015-264],[@b4-crt-2015-264]\], gastric cancer-specific survival \[[@b3-crt-2015-264]\], and relapse-free survival \[[@b2-crt-2015-264]\]. In addition, gastric cancers in patients without *H. pylori* infection had poorer clinicopathological features compared with those in patients with *H. pylori* infection, including larger tumor size, more advanced stage, and more frequent lymph node or distant metastases \[[@b3-crt-2015-264]-[@b7-crt-2015-264]\].

However, *H. pylori* eradication or *H. pylori*--negative status after endoscopic resection for gastric cancer has been associated with a reduced risk for development of metachronous cancers in the remnant stomach \[[@b8-crt-2015-264],[@b9-crt-2015-264]\]. In addition, *H. pylori* eradication leads to improvement of premalignant conditions, such as mucosal atrophy and intestinal metaplasia, in the remnant stomach after gastrectomy \[[@b10-crt-2015-264],[@b11-crt-2015-264]\]. Therefore, *H. pylori* eradication may have beneficial effects, including the potential prevention of metachronous cancers after gastrectomy.

In a previous double-blind randomized controlled study, we reported that *H. pylori* eradication improved the histological changes of the remnant stomach mucosa, such as atrophy and intestinal metaplasia, after subtotal gastrectomy for gastric cancer \[[@b10-crt-2015-264]\]. In the current study, we evaluated long-term outcomes, including survival and cancer recurrence, to determine whether *H. pylori* eradication has a detrimental effect on long-term survival after distal gastrectomy for gastric cancer.

Materials and Methods
=====================

1. Study population
-------------------

We observed patients enrolled in a previous double-blind randomized controlled trial evaluating the effects of *H. pylori* eradication on mucosal atrophy and intestinal metaplasia in the remnant stomach after distal gastrectomy \[[@b10-crt-2015-264]\]. Detailed methods were described previously. In brief, newly diagnosed gastric cancer patients aged 18 to 70 years were recruited and screened for eligibility at the National Cancer Center, Korea, between August 2003 and May 2006. Eligibility criteria were as follows: distal gastric adenocarcinoma of clinical stage IA, IB, II, or IIIA according to the 6th edition of the International Union Against Cancer/American Joint Committee on Cancer TNM classification system \[[@b12-crt-2015-264]\], and positive tests for *H. pylori* infection. Informed consent was obtained from all participants. The Institutional Review Board of the National Cancer Center, Korea, approved the study protocol (NCCCTS03-063) and the original trial was registered with ClinicalTrials.gov (NCT01002443) \[[@b10-crt-2015-264]\].

2. *H. pylori* status evaluation
--------------------------------

Both the rapid urea test (RUT) and histology before distal gastrectomy were used for assessment of *H. pylori* infection. On the initial esophagogastroduodenoscopy (EGD), six biopsy specimens were taken from the lesser curvature of the antrum and the lesser and greater curvatures of the corpus for evaluation of *H. pylori* status, mucosal atrophy, and intestinal metaplasia. The collected biopsy specimens were immediately fixed in neutral-buffered 10% formalin, embedded in paraffin blocks, and stained with hematoxylin-eosin and Wright-Giemsa for histological evaluation. A single pathologist (M.-C.K.) performed pathological evaluation. One additional biopsy specimen was taken from the greater curvature of the corpus for RUT (Proton Dry, Medical Instruments Corporation, Solothurn, Switzerland). Patients confirmed as *H. pylori* infection by both a positive RUT and histological evaluation were enrolled in the study.

3. Randomization and surgery
----------------------------

Eligible patients were randomly assigned to the treatment group or the placebo group by computer-generated random number. All investigators and patients were blinded to the randomization results throughout the trial. The treatment group received proton pump inhibitor (PPI)--based standard triple therapy, consisting of rabeprazole 10 mg, clarithromycin 500 mg, and amoxicillin 1,000 mg twice daily for 7 days. The placebo group received the same schedule of rabeprazole 10 mg but received a placebo rather than clarithromycin and amoxicillin. These treatments were administered before distal gastrectomy. Then, all patients underwent an open or laparoscopic distal gastrectomy with D1+ or D2 lymph node dissection \[[@b13-crt-2015-264]\]. The reconstruction methods were Billroth I (gastroduodenostomy) or II (gastrojejunostomy).

4. Follow-up *H. pylori* status
-------------------------------

Follow-up EGDs with biopsy, RUT, and urea breath test (UBT) were performed at 3 months after distal gastrectomy for assessment of *H. pylori* status. The biopsy specimens were taken from the lesser and greater curvatures of the corpus, but not the antrum. At the follow-up examination, *H. pylori* was considered negative if all three tests were negative.

5. Statistical analysis
-----------------------

The calculation of study sample size was described in detail previously \[[@b10-crt-2015-264]\]. In the current study, outcomes were OS, gastric cancer-specific death, and gastric cancer recurrence. OS and gastric cancer-specific survival were determined from the time of distal gastrectomy to death; OS included deaths from any cause, but gastric cancer-specific death included only death from gastric cancer. Gastric cancer recurrence included metachronous cancer in the remnant stomach, lymph node metastasis, and distant organ metastasis occurring after gastrectomy for distal gastrectomy.

Continuous variables were compared using the Mann-Whitney U test and categorical variables were compared using the chi-square test or Fisher exact test. Follow-up data on deaths and recurrences were obtained until December 2014. The Kaplan-Meier method was used for construction of survival curves, and comparisons were performed using the log-rank test. Comparisons of gastric cancer-specific death and gastric cancer recurrence rates were performed using Gray's test because of the possible competing risk of death without recurrence. A multivariate Cox proportional hazards model analysis was performed for overall mortality, and a multivariate Fine-Gray regression model analysis was performed for cancer recurrence with competing risks. In model 1, multivariate analyses were performed according to the allocated groups, and in model 2, analyses were performed according to the *H. pylori* status at 3 months after gastrectomy. Covariates for multivariate analyses were age, sex, and variables having a p-value less than 0.1 in univariate analyses. Analyses were performed using STATA ver. 12.1 (Stata Corp., College Station, TX), except for the Gray's test, which was analyzed using SAS ver. 9.3 (SAS Inc., Cary, NC). A p-value less than 0.05 was considered statistically significant.

Results
=======

Of the 190 randomized patients, 169 patients who received treatment or placebo were included in the analyses; 87 in the treatment group and 82 in the placebo group. At 3 months after distal gastrectomy, *H. pylori* infection status was evaluated using UBT, histology, and RUT in 167 patients; 67 patients in the treatment group (81.7%, 67/86 patients) and 15 patients in the placebo group (18.3%, 15/81 patients) were negative for *H. pylori* infection ([Fig. 1](#f1-crt-2015-264){ref-type="fig"}). These patients were included in the analyses according to the *H. pylori* status at 3 months after distal gastrectomy.

Baseline characteristics of the 169 allocated patients and 167 patients who underwent follow-up *H. pylori* tests at 3 months after gastrectomy are summarized in [Table 1](#t1-crt-2015-264){ref-type="table"}. Median age was 57 years (interquartile range \[IQR\], 48 to 64 years) and the proportion of male patients was 69.2% (117 patients). There were no differences in age, sex, smoking, alcohol drinking, surgical methods, reconstruction methods, pathologic stage, and histology between the treatment and placebo groups. Comparisons according to *H. pylori* status at 3 months after gastrectomy showed no significant differences in baseline characteristics except for the final cancer stage after surgery; a higher proportion of patients with *H. pylori*positive status had stage I cancer compared to those with *H. pylori*-negative status (80.0% vs. 72.0%, respectively; p=0.033).

1. Comparisons of long-term survival rates after distal gastrectomy
-------------------------------------------------------------------

During a median follow-up period of 9.4 years (IQR, 9.0 to 10.2 years; range, 0.7 to 11.3 years), 26 patients died: 14 in the treatment group and 12 in the placebo group. The 5-year OS rates were 98.9% in the treatment group and 91.5% in the placebo group, and results of Kaplan-Meier analysis showed no significant difference between groups (p=0.957 by log-rank test) ([Fig. 2A](#f2-crt-2015-264){ref-type="fig"}). Overall, 13 patients had gastric cancer recurrence (6 \[6.9%\] in the treatment group and 7 \[8.5%\] in the placebo group). Of these, metachronous cancers occurred in 4 patients (3 patients in the treatment group and 1 patient in the placebo group), and the metachronous cancer rates were not different between the treatment group and the placebo group (3.5% vs. 1.5%, p=0.341). One patient died of gastric cancer metastasis at 5 months after total gastrectomy for metachronous cancer, while, the remaining nine patients had lymph node or other organ metastases (3 patients in the treatment group and 6 patients in the placebo group). Of the patients with gastric cancer recurrence, 10 patients died because of gastric cancer recurrence (4 patients in the treatment group and 6 patients in the placebo group). The 5-year incidence rates of gastric cancer recurrence were 4.6% in the treatment group and 8.5% in the placebo group, and Gray's test showed no statistical significance (p=0.652) ([Fig. 2B](#f2-crt-2015-264){ref-type="fig"}). No difference in the cumulative incidences of gastric cancer-specific death were observed between the treatment and placebo groups (5-year cumulative incidence rate, 1.1% vs. 6.1%, respectively; p=0.422 by Gray's test) ([Fig. 2C](#f2-crt-2015-264){ref-type="fig"}).

At 3 months after gastrectomy, 82 patients had negative *H. pylori* status and 85 had positive *H. pylori* status. After gastrectomy, OS did not differ between patients with negative *H. pylori* status and those with positive *H. pylori* status (5-year OS rates, 96.3% vs. 94.1%, respectively; p=0.997 by log-rank test) ([Fig. 3A](#f3-crt-2015-264){ref-type="fig"}). In addition, no statistical differences in gastric cancer recurrence (5-year cumulative incidence rates, 6.1% for negative status vs. 7.1% for positive status; p=0.897 by Gray's test) ([Fig. 3B](#f3-crt-2015-264){ref-type="fig"}) and gastric cancer-specific death (5-year cumulative incidence rates, 3.7% for negative status vs. 3.5% for positive status; p=0.792 by Gray's test) ([Fig. 3C](#f3-crt-2015-264){ref-type="fig"}) were observed between patients with and without *H. pylori* at 3 months after distal gastrectomy.

2. Univariate and multivariate analyses for overall mortality and cancer recurrence
-----------------------------------------------------------------------------------

In univariate analyses, overall mortality after distal gastrectomy was not affected by *H. pylori* treatment allocation (crude hazard ratio \[cHR\] for *H. pylori* treatment, 1.02; p=0.957) or positive *H. pylori* status at 3 months after distal gastrectomy (cHR for *H. pylori*--positive, 1.00; p=0.997). Male sex, Billroth II anastomosis after distal gastrectomy, and stage ≥ IIIa were significant factors associated with overall mortality. In model 1, multivariate analysis according to *H. pylori* treatment allocation showed that age (adjusted HR \[aHR\], 1.06; p=0.017), male sex (aHR, 8.38; p=0.005), and advanced stage ≥ IIIa (aHR, 9.18; p \< 0.001) were independent risk factors for overall mortality. *H. pylori* treatment was not a significant factor for overall mortality (aHR for treatment group, 0.75; p=0.495). In model 2, positive *H. pylori* status at 3 months after gastrectomy did not show significant association with overall mortality (aHR, 1.16; p=0.715), whereas age, male sex, and advanced stage ≥ IIIa were independent risk factors for overall mortality ([Table 2](#t2-crt-2015-264){ref-type="table"}).

For cancer recurrence, neither *H. pylori* treatment (cHR, 0.78; p=0.649) nor positive *H. pylori* status after gastrectomy (cHR, 1.13; p=0.821) were significant factors in univariate analyses. Multivariate Fine-Gray regression analyses showed that only the advanced stage ≥ IIIa was a significant risk factor in both model 1 and 2. In these analyses, *H. pylori* treatment (aHR, 0.60; p=0.431) and positive *H. pylori* status at 3 months after distal gastrectomy (aHR, 1.05; p=0.921) did not affect cancer recurrence ([Table 3](#t3-crt-2015-264){ref-type="table"}).

Discussion
==========

In the current long-term follow-up study of a double-blind randomized trial, *H. pylori* treatment and *H. pylori* infection status did not affect long-term outcomes after distal gastrectomy, including OS, gastric cancer recurrence, and gastric cancer-specific death. Several studies have reported an association of *H. pylori* infection status with long-term outcomes after gastrectomy. One prospective \[[@b2-crt-2015-264]\] and two retrospective studies \[[@b3-crt-2015-264],[@b4-crt-2015-264]\] reported that negative *H. pylori* status is a poor prognostic factor for long-term outcomes after gastrectomy. Meimarakis et al. \[[@b2-crt-2015-264]\] reported that negative *H. pylori* status after surgery is an independent risk factor associated with poor OS and recurrence-free survival, and Marrelli et al. \[[@b3-crt-2015-264]\] reported that negative *H. pylori* status is a poor prognostic factor for OS. Kang et al. \[[@b4-crt-2015-264]\] reported an association of negative *H. pylori* status with poor OS in patients who received adjuvant chemotherapy for locally advanced gastric cancer (stage IB to IV) after gastrectomy. In these studies, the negative *H. pylori* status group likely included heterogeneous patients who were initially negative for *H. pylori* infection or those whose *H. pylori* infection disappeared because of the advances of atrophy or *H. pylori* treatment. It appears that negative *H. pylori* status due to any cause may affect long-term survival after gastrectomy. However, our findings suggest that negative *H. pylori* status resulting from *H. pylori* treatment does not affect long-term outcomes after distal gastrectomy.

In comparison with *H. pylori*--positive gastric cancer,*H. pylori*--negative gastric cancer had the following clinical characteristics: prevalence in younger patients, tumor location in the upper-third portion of the stomach, and more frequent diffuse-type histology \[[@b5-crt-2015-264],[@b7-crt-2015-264],[@b14-crt-2015-264]\]. In addition, *H. pylori*--negative patients had higher advanced cancer stage \[[@b5-crt-2015-264]\] or distant metastasis \[[@b7-crt-2015-264]\], suggesting poor clinical outcomes. In the aforementioned studies that reported poorer long-term survival rates after gastrectomy in *H. pylori*--negative gastric cancer patients, baseline clinical characteristics were also different between *H. pylori*--negative and --positive groups. *H. pylori*--negative patients had a significantly higher proportion of tumors located proximally \[[@b2-crt-2015-264],[@b3-crt-2015-264]\], and more of these patients underwent total gastrectomy \[[@b2-crt-2015-264]\]. *H. pylori*--negative patients had more advanced tumor stage \[[@b3-crt-2015-264],[@b4-crt-2015-264]\] and larger tumor size \[[@b4-crt-2015-264]\] than *H. pylori*--positive patients. These findings suggest that *H. pylori*--negative gastric cancer may be intrinsically associated with poor clinicopathological features. In a recent study, gastric cancers were classified according to molecular subtype \[[@b15-crt-2015-264]\]. *H. pylori* infection is also related to some of the molecular changes associated with gastric carcinogenesis, including genetic instability and epigenetic changes in oncogenes or tumor suppressor genes \[[@b16-crt-2015-264]\]. Different molecular changes are likely in *H. pylori*--negative gastric cancer compared with *H. pylori*--positive gastric can cer, which may be associated with poor long-term outcomes.

A possible mechanism for the prognostic role of *H. pylori* infection after gastrectomy is that *H. pylori*--induced tumor-specific immune responses may be down-regulated in *H. pylori*--negative gastric cancer patients, possibly influencing long-term outcomes \[[@b2-crt-2015-264]\]. However, this mechanism has not been proven in clinical studies, and other factors could affect the outcomes for these patients. In the current study, long-term outcomes were not affected by *H. pylori* status after gastrectomy; however, age, male sex, and advanced stage were independent risk factors for overall mortality. Advanced stage was also a significant risk factor for cancer recurrence. In addition, Hobsley et al. \[[@b17-crt-2015-264]\] commented that negative *H. pylori* status might simply be associated with more advanced tumor progression rather than related to poor prognosis, consistent with our findings.

In our previous study, most *H. pylori*--negative gastric cancers occurred in patients with past *H. pylori* infection, and patients who were truly negative for *H. pylori* infection were rare, occurring at a rate of 2.3% \[[@b7-crt-2015-264]\]. Compared with true *H. pylori*--negative gastric cancer patients, gastric cancer patients with past *H. pylori* infection were older and predominantly male, and had a higher proportion of intestinal-type histology and a lower distant metastasis rate \[[@b7-crt-2015-264]\]. In the current study, *H. pylori*--negative patients were those with past *H. pylori* infection that was eradicated upon treatment with PPI-based standard triple therapy. Clinical characteristics of patients in the *H. pylori*--negative group may be different from those of true *H. pylori*--negative gastric cancer patients, and in this instance, long-term outcomes after distal gastrectomy were not affected by *H. pylori* treatment.

Because of the possible roles of *H. pylori* infection in carcinogenesis in the remnant stomach mucosa after treatment of gastric cancer \[[@b18-crt-2015-264]\], guidelines recommend *H. pylori* eradication to prevent development of new cancers in patients who undergo distal gastrectomy \[[@b1-crt-2015-264]\]. In patients undergoing gastrectomy, *H. pylori* infection may induce chronic and active gastritis, and is associated with increased corpus mucosal cell proliferation in the remnant stomach \[[@b18-crt-2015-264]-[@b20-crt-2015-264]\]. By contrast, *H. pylori*--negative status is associated with a low risk of mucosal atrophy and intestinal metaplasia in the remnant stomach after gastrectomy \[[@b10-crt-2015-264],[@b11-crt-2015-264],[@b18-crt-2015-264],[@b21-crt-2015-264]\]. In addition, in early gastric cancer patients undergoing endoscopic resection, a previous randomized controlled study reported that *H. pylori* treatment reduces the incidence of metachronous cancers \[[@b8-crt-2015-264]\], and a recent meta-analysis also reported significantly reduced incidences of metachronous gastric neoplasia for *H. pylori*--eradicated patients \[[@b22-crt-2015-264]\]. However, in the current study metachronous cancer rates were not different according to *H. pylori* treatment or according to *H. pylori* status. This may be because all of the included patients underwent gastric resection of the distal portion of the stomach, which is the common site for synchronous \[[@b23-crt-2015-264]\] or metachronous cancer \[[@b24-crt-2015-264]\]. Studies with a proper design and adequate sample size are needed to evaluate the question of whether *H. pylori* eradication may be a preventive strategy for development of metachronous gastric cancer after distal gastrectomy.

The main strength of this study was that it collected long-term follow-up data from gastric cancer patients who underwent distal gastrectomy in a prospective double-blind randomized controlled trial. Thus, we performed intention-to-treat analysis to determine whether *H. pylori* treatment affects long-term outcomes after distal gastrectomy in gastric cancer patients.

However, the current study had several limitations. First, the study sample size may not be large enough to evaluate the association between *H. pylori* infection status and long-term outcomes, because the sample size originally calculated was for the first study, which assessed the histological improvement of the lessor curvature of the corpus after distal gastrectomy \[[@b10-crt-2015-264]\]. Thus, an additional study including more enrolled patients is needed to provide adequate power. Second, the findings of the current study may not be applicable to areas where the prevalence of *H. pylori* infection and the incidence of gastric cancer are low. Third, spontaneous clearance of *H. pylori* infection during follow-up after gastrectomy was reported in the previous study \[[@b25-crt-2015-264]\]. Therefore, some *H. pylori*-positive patients in the current study might have spontaneous negative conversion of *H. pylori* infection after distal gastrectomy, and long-term outcomes might be affected by the spontaneous clearance of *H. pylori* infection. Finally, clinicopathological characteristics according to the virulence factors of *H. pylori* strains were not evaluated in the current study.

Conclusion
==========

In conclusion, *H. pylori* eradication for gastric cancer patients who undergo distal gastrectomy appears to have no effect on long-term survival and cancer recurrence rates after surgery. Thus, *H. pylori* eradication in gastric cancer patients after distal gastrectomy may be performed without concern for compromising long-term survival.
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###### 

Baseline characteristics

  Characteristic                         Initial allocation group   *Helicobacter pylori* status at 3 months after surgery                                     
  -------------------------------------- -------------------------- -------------------------------------------------------- ------- ------------ ------------ ----------
  **Age, median (IQR, yr)**              56 (48-64)                 58 (48-65)                                               0.715   57 (46-64)   58 (48-64)   0.743
  **Sex**                                                                                                                                                      
   Female                                21 (25.6)                  31 (35.6)                                                0.158   25 (30.5)    27 (31.8)    0.859
   Male                                  61 (74.4)                  56 (64.4)                                                        57 (69.5)    58 (68.2)    
  **Allocation group**                                                                                                                                         
   Placebo                               \-                         \-                                                       \-      15 (18.3)    66 (77.7)    \< 0.001
   Treatment                             \-                         \-                                                               67 (81.7)    19 (22.4)    
  **Alcohol drinking**                                                                                                                                         
   No                                    35 (42.7)                  40 (46.0)                                                0.667   38 (46.3)    36 (42.4)    0.604
   Yes                                   47 (57.3)                  47 (54.0)                                                        44 (53.7)    49 (57.7)    
  **Smoking**                                                                                                                                                  
   No                                    51 (62.2)                  46 (52.9)                                                0.221   47 (57.3)    49 (57.7)    0.996
   Yes                                   31 (37.8)                  41 (47.1)                                                        35 (42.7)    36 (42.4)    
  **Surgical method**                                                                                                                                          
   Laparoscopic                          21 (25.6)                  17 (19.5)                                                0.345   15 (18.3)    22 (25.9)    0.238
   Open                                  61 (74.4)                  70 (80.5)                                                        67 (81.7)    63 (74.1)    
  **Reconstruction method**                                                                                                                                    
   Billroth I (gastroduodenostomy)       63 (76.8)                  59 (67.8)                                                0.191   59 (72.0)    61 (71.8)    0.979
   Billroth II (gastrojejunostomy)       19 (23.2)                  28 (32.2)                                                        23 (28.1)    24 (28.2)    
  **Histologic type**                                                                                                                                          
   Differentiated                        48 (58.5)                  51 (58.6)                                                0.991   45 (54.9)    54 (63.5)    0.255
   Undifferentiated                      34 (41.5)                  36 (41.4)                                                        37 (45.1)    31 (36.5)    
  **Final cancer stage after surgery**                                                                                                                         
   Stage I                               66 (80.5)                  63 (72.4)                                                0.257   59 (72.0)    68 (80.0)    0.033
   Stage II                              10 (12.2)                  19 (21.8)                                                        20 (24.4)    9 (10.6)     
   Stage IIIa or more                    6 (7.3)                    5 (5.8)                                                          3 (3.7)      8 (9.4)      

Values are presented as number (%) unless otherwise indicated. IQR, interquartile range.

###### 

Clinical and pathological factors associated with overall mortality

  Factor                                                                                                     No.   Univariate analysis^[a)](#tfn3-crt-2015-264){ref-type="table-fn"}^   Multivariate analysis^[a)](#tfn3-crt-2015-264){ref-type="table-fn"}^                                  
  ---------------------------------------------------------------------------------------------------------- ----- -------------------------------------------------------------------- ---------------------------------------------------------------------- ------------------- ---------- --
  **Model 1. *Helicobacter pylori* allocation group**                                                                                                                                                                                                                                         
   Allocation group                                                                                                                                                                                                                                                                           
    Placebo                                                                                                  82    1.00                                                                                                                                        1.00                           
    Treatment                                                                                                87    1.02 (0.47-2.21)                                                     0.957                                                                  0.75 (0.32-1.73)    0.495      
   Age (yr)                                                                                                  169   1.04 (0.99-1.08)                                                     0.119                                                                  1.06 (1.01-1.11)    0.017      
   Sex                                                                                                                                                                                                                                                                                        
    Female                                                                                                   52    1.00                                                                                                                                        1.00                           
    Male                                                                                                     117   6.11 (1.44-25.87)                                                    0.014                                                                  8.38 (1.87-37.42)   0.005      
   Alcohol drinking                                                                                                                                                                                                                                                                           
    No                                                                                                       75    1.00                                                                                                                                        \-                             
    Yes                                                                                                      94    1.23 (0.56-2.69)                                                     0.612                                                                  \-                  \-         
   Smoking                                                                                                                                                                                                                                                                                    
    No                                                                                                       97    1.00                                                                                                                                        \-                             
    Yes                                                                                                      72    1.50 (0.69-3.24)                                                     0.305                                                                  \-                  \-         
   Surgical method                                                                                                                                                                                                                                                                            
    Laparoscopic                                                                                             38    1.00                                                                                                                                        1.00                           
    Open                                                                                                     131   3.77 (0.89-15.97)                                                    0.071                                                                  2.10 (0.47-9.43)    0.335      
   Reconstruction method                                                                                                                                                                                                                                                                      
    Billroth I (gastroduodenostomy)                                                                          122   1.00                                                                                                                                        1.00                           
    Billroth II (gastrojejunostomy)                                                                          47    3.10 (1.42-6.74)                                                     0.004                                                                  1.56 (0.62-3.92)    0.344      
   Histologic type                                                                                                                                                                                                                                                                            
    Differentiated                                                                                           99    1.00                                                                                                                                        \-                             
    Undifferentiated                                                                                         70    0.68 (0.30-1.53)                                                     0.348                                                                  \-                  \-         
   Final cancer stage after surgery                                                                                                                                                                                                                                                           
    Stage I                                                                                                  129   1.00                                                                                                                                        1.00                           
    Stage II                                                                                                 29    1.63 (0.58-4.60)                                                     0.355                                                                  1.80 (0.59-5.46)    0.298      
    Stage IIIa or more                                                                                       11    10.45 (4.31-25.38)                                                   \< 0.001                                                               9.18 (3.25-25.97)   \< 0.001   
  **Model 2. *H. pylori* status at 3 months after surgery**^[b)](#tfn4-crt-2015-264){ref-type="table-fn"}^                                                                                                                                                                                    
   *H. pylori* status at 3 months after surgery                                                                                                                                                                                                                                               
    Negative                                                                                                 82    1.00                                                                                                                                        1.00                           
    Positive                                                                                                 85    1.00 (0.46-2.16)                                                     0.997                                                                  1.16 (0.52-2.57)    0.715      

cHR, crude hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio.

Cox proportional hazards model was used for uni- and multivariate analyses,

Covariates for multivariate analysis in model 2 were age, sex, operation method, reconstruction method, and final cancer stage after surgery.

###### 

Clinical and pathological factors associated with gastric cancer recurrence

  Factor                                                                                                     No.   Univariate analysis^[a)](#tfn6-crt-2015-264){ref-type="table-fn"}^   Multivariate analysis^[a)](#tfn6-crt-2015-264){ref-type="table-fn"}^                               
  ---------------------------------------------------------------------------------------------------------- ----- -------------------------------------------------------------------- ---------------------------------------------------------------------- ------------------- ------- --
  **Model 1. *Helicobacter pylori* allocation group**                                                                                                                                                                                                                                      
   Allocation group                                                                                                                                                                                                                                                                        
    Placebo                                                                                                  82    1.00                                                                                                                                        1.00                        
    Treatment                                                                                                87    0.78 (0.26-2.29)                                                     0.649                                                                  0.60 (0.17-2.12)    0.431   
   Age (yr)                                                                                                  169   1.03 (0.96-1.10)                                                     0.359                                                                  1.06 (0.99-1.13)    0.101   
   Sex                                                                                                                                                                                                                                                                                     
    Female                                                                                                   52    1.00                                                                                                                                        1.00                        
    Male                                                                                                     117   2.50 (0.55-11.35)                                                    0.236                                                                  3.38 (0.56-20.54)   0.185   
   Alcohol drinking                                                                                                                                                                                                                                                                        
    No                                                                                                       75    1.00                                                                                                                                        \-                          
    Yes                                                                                                      94    1.31 (0.44-3.96)                                                     0.629                                                                  \-                  \-      
   Smoking                                                                                                                                                                                                                                                                                 
    No                                                                                                       97    1.00                                                                                                                                        \-                          
    Yes                                                                                                      72    2.27 (0.75-6.85)                                                     0.145                                                                  \-                  \-      
   Surgical method                                                                                                                                                                                                                                                                         
    Laparoscopic                                                                                             38    1.00                                                                                                                                        \-                          
    Open                                                                                                     131   1.63 (0.36-7.33)                                                     0.527                                                                  \-                  \-      
   Reconstruction method                                                                                                                                                                                                                                                                   
    Billroth I (gastroduodenostomy)                                                                          122   1.00                                                                                                                                        1.00                        
    Billroth II (gastrojejunostomy)                                                                          47    3.22 (1.10-9.47)                                                     0.033                                                                  2.13 (0.48-9.40)    0.319   
   Histologic type                                                                                                                                                                                                                                                                         
    Differentiated                                                                                           99    1.00                                                                                                                                        \-                          
    Undifferentiated                                                                                         70    0.61 (0.19-2.00)                                                     0.416                                                                  \-                  \-      
   Final cancer stage after surgery                                                                                                                                                                                                                                                        
    Stage I                                                                                                  129   1.00                                                                                                                                        1.00                        
    Stage II                                                                                                 29    2.30 (0.56-9.44)                                                     0.247                                                                  2.50 (0.44-14.03)   0.299   
    Stage IIIa or more                                                                                       11    8.76 (2.58-29.70)                                                    \< 0.001                                                               7.44 (1.55-35.58)   0.012   
  **Model 2. *H. pylori* status at 3 months after surgery**^[b)](#tfn7-crt-2015-264){ref-type="table-fn"}^                                                                                                                                                                                 
   *H. pylori* status at 3 months after surgery                                                                                                                                                                                                                                            
    Negative                                                                                                 82    1.00                                                                                                                                        1.00                        
    Positive                                                                                                 85    1.13 (0.38-3.35)                                                     0.821                                                                  1.05 (0.37-2.97)    0.921   

cHR, crude hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio.

Fine-Gray regression model was used for uniand multivariate analyses,

Covariates for multivariate analysis in model 2 were age, sex, reconstruction method, and final cancer stage after surgery.
